HHS directs FDA not to enforce rules against certain wellness peptides

The Department of Health and Human Services policy follows pushback from FDA scientists regarding unproven injectable peptides.

HHS directs FDA not to enforce rules against certain wellness peptides
Photo: The Guardian

The Department of Health and Human Services (HHS) has issued a policy directing the FDA not to take action against specialty pharmacies that sell a half-dozen wellness peptides. These substances include BPC-157, TB-500 and KPV. The chemicals have not been approved as safe and effective by the FDA.

The effort to loosen rules on these unproven peptide drugs was driven almost entirely by HHS and faced pushback from FDA drug staffers. Scientists warned the move could undermine the agency's mission of keeping unproven health products off the US market. HHS officials initially wanted the FDA to draft an official regulation to add these peptides to a list of substances deemed safe for use by compounding pharmacies.

Robert F Kennedy Jr, who has called himself a 'big fan' of peptides, recently described using BPC-157 to treat a muscle injury. Kennedy has said US compounding pharmacies must be allowed to sell peptides because Americans are turning to 'gray market' products imported from China and other countries.

The new HHS document represents a step back from original plans and avoids a direct confrontation with FDA staffers by only directing the FDA not to enforce certain rules. HHS ultimately included safety measures suggested by FDA staffers. These include requiring pharmacies to use peptide ingredients from FDA-registered factories, collecting information on side-effects for safety analysis, and verifying the chemical identity of peptides.

Key facts

  • The HHS policy directs the FDA not to enforce rules against pharmacies compounding BPC-157, TB-500 and KPV.
  • FDA staffers warned that the peptides remain unproven in terms of safety and effectiveness.
  • In 2023, the FDA added several peptides to a list of substances that should not be compounded due to risks of kidney damage, tumor growth and allergic reactions.

Three perspectives

Neutral

The HHS policy directs the FDA not to enforce rules against specialty pharmacies selling certain wellness peptides.

Positive

The new policy includes safety measures such as requiring pharmacies to use ingredients from FDA-registered factories and collect side-effect information.

Negative

FDA scientists warned that the effort to loosen rules on unproven peptides could undermine the agency's mission to keep unsafe products off the market.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition